Inclusion Criteria:
EX VIVO STUDY IN PATIENTS WITH UC
PATIENTS WITH UC:
* Over 18 years old.
* Diagnosis of UC according to the criteria of the European Crohn's and Colitis Organisation (ECCO).
* Previous treatments are allowed, provided they have remained stable for the past 3 months.
* In the case of patients with active UC, they should have endoscopic activity within 1 month of starting the treatment (Mayo endoscopic sub-index of ≥ 2).
* Women of childbearing age using contraceptive methods with an error rate \<1% per year. Examples of contraceptive methods whose error rate is \<1% per year are:
1. Intrauterine device (IUD).
2. Bilateral tubal occlusion.
3. Couple with vasectomy.
4. Sexual abstinence.
INDIVIDUALS WITHOUT UC:
* Over 18 years old.
* Subjects not diagnosed with UC, or other inflammatory allergic, malignant or autoimmune diseases.
* Women of childbearing age using contraceptive methods with an error rate \<1% per year. Examples of contraceptive methods whose error rate is \<1% per year are:
1. Intrauterine device (IUD).
2. Bilateral tubal occlusion.
3. Couple with vasectomy.
4. Sexual abstinence.
IN VIVO STUDY IN PATIENTS WITH UC
PATIENTS WITH UC:
* Over 18 years old.
* Diagnosis of UC according to the criteria of the European Crohn's and Colitis Organisation (ECCO).
* Have indication of treatment with anti-TNFα (infliximab, adalimumab or golimumab) o tofacitinib.
* Be the first received JAK-inhibitor or anti-TNFα with a given mechanism of action.
* Have endoscopic activity of UC within 1 month of starting the treatment (Mayo endoscopic sub-index of ≥ 2).
* Previous treatments (including corticosteroids and immunosuppressants) are allowed provided that they have been stable for the last 3 months before beginning treatment with JAK-inhibitor or anti-TNFα and that they are maintained at a stable dose for the duration of the study
* Women of childbearing age using contraceptive methods with an error rate \<1% per year. Examples of contraceptive methods whose error rate is \<1% per year are:
1. Intrauterine device (IUD).
2. Bilateral tubal occlusion.
3. Couple with vasectomy.
4. Sexual abstinence.
INDIVIDUALS WITHOUT UC:
* Over 18 years old.
* Subjects not diagnosed with UC, or other inflammatory, allergic, malignant or autoimmune diseases.
* Women of childbearing age using contraceptive methods with an error rate \<1% per year. Examples of contraceptive methods whose error rate is \<1% per year are:
1. Intrauterine device (IUD).
2. Bilateral tubal occlusion.
3. Couple with vasectomy.
4. Sexual abstinence.
Exclusion Criteria:
EX VIVO STUDY IN PATIENTS WITH UC
PATIENTS WITH UC:
* Under 18 years old.
* Immune-mediated disease, neoplasm or active infection.
* Pregnancy or lactation.
* Alcohol or drug abuse.
* Ostomy.
* Abdominal surgery in the last 6 months.
* Colectomy.
* Active infection with hepatitis B, C or HIV virus.
* Medical history of thromboembolic events.
* Treatment with anticoagulants, antiplatelets or other drugs that alter the coagulation.
* Use of combined hormonal contraceptives or hormone replacement therapy.
* Hereditary coagulation disorders.
* Refusal to give consent for participation in the study.
INDIVIDUALS WITHOUT UC:
* Under 18 years of age.
* Advanced chronic disease or any other pathology that prevents the monitoring of the protocol of this study.
* Pregnancy or lactation.
* Alcohol or drug abuse.
* Ostomy.
* Abdominal surgery in the last 6 months.
* Colectomy.
* Active infection with hepatitis B, C or HIV virus.
* Medical history of thromboembolic events.
* Treatment with anticoagulants, antiplatelets or other drugs that alter the coagulation.
* Use of combined hormonal contraceptives or hormone replacement therapy.
* Hereditary coagulation disorders.
* Refusal to give consent for participation in the study.
IN VIVO STUDY IN PATIENTS WITH UC
PATIENTS WITH UC:
* Under 18 years old.
* Immune-mediated disease.
* Neoplasm or active infection.
* Pregnancy or lactation.
* Alcohol or drug abuse.
* Ostomy.
* Colectomy.
* Active infection with hepatitis B, C or HIV virus.
* Indication of anti-TNFα or JAK-inhibitors treatment for a cause other than UC.
* Have previously received a drug with the same mechanism of action (anti-TNFα or JAK-inhibitors)
* Medical history of thromboembolic events.
* Treatment with anticoagulants, antiplatelets or other drugs that alter the coagulation.
* Use of combined hormonal contraceptives or hormone replacement therapy.
* Hereditary coagulation disorders.
* Refusal to give consent for participation in the study.
INDIVIDUALS WITHOUT UC:
* Under 18 years of age.
* Advanced chronic disease or any other pathology that prevents the monitoring of the protocol of this study.
* Pregnancy or lactation.
* Alcohol or drug abuse.
* Active infection with hepatitis B, C or HIV virus.
* Finding of macroscopic alterations during the colonoscopy or finding of relevant inflammatory alterations in the biopsies obtained during the colonoscopy.
* Treatment with immunomodulators, immunosuppressants, corticosteroids or other drugs that alter the immune system.
* Medical history of thromboembolic events.
* Treatment with anticoagulants, antiplatelets or other drugs that alter the coagulation.
* Use of combined hormonal contraceptives or hormone replacement therapy.
* Hereditary coagulation disorders.
* Refusal to give consent for participation in the study.
* Abdominal surgery in the last 6 months.
